A case of ALK-associated non-small-cell lung cancer with evidence of omental metastasis 6 years after initial presentation

Author： Kulkarni Sameer   Kabbinavar Fairooz   Eshaghian Shahrooz  

Publisher： Future Medicine

ISSN： 1758-1966

Source： Lung Cancer Management, Vol.2, Iss.3, 2013-06, pp. : 199-204

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EML4-ALK translocation is associated with early onset of disease and other clinicopathological features in Chinese female never-smokers with non-small-cell lung cancer

By              

Oncology Letters, Vol. 10, Iss. 6, 2015-01 ,pp. : 3385-3392

Spandidos Publications

Access to resources Recommend Favorite

β-blockers and metastasis in non-small-cell lung cancer

By Wang Hongmei   Gomez Daniel R   Liao Zhongxing  

Expert Review of Anticancer Therapy, Vol. 13, Iss. 6, 2013-06 ,pp. : 641-643

Informa Healthcare

Access to resources Recommend Favorite

Ask the Experts: Managing non-small-cell lung cancer with acquired resistance to EGF receptor and ALK inhibitors

By Lee Siow-Ming   King Judy  

Lung Cancer Management, Vol. 2, Iss. 1, 2013-02 ,pp. : 23-26

Future Medicine

Access to resources Recommend Favorite

Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer

By Marinopoulos Spyridon   Skorda Lamprini   Karatapanis Stylianos   Rasidakis Antonis  

Medical Oncology, Vol. 25, Iss. 4, 2008-12 ,pp. : 415-418

Humana Press, Inc

Access to resources Recommend Favorite

Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer

By  

International Journal of Oncology, Vol. 46, Iss. 3, 2015-03 ,pp. : 1025-1030

Spandidos Publications

Access to resources Recommend Favorite